In a world where doctors are required to make an average of three drug visits a day, patients are forced to pay for those visits.

But there are ways to cut that out, and that’s where a new startup is helping.

Emerald Health Care Solution’s CEO, Ryan J. Jankiewicz, believes the company is the next frontier in the healthcare business.

“We’re going to do this in a way that we don’t have to pay doctors to do it,” Jankowicz told Business Insider.

“We’re trying to change the system in a whole host of ways, from pricing to the way we provide the services.”

The startup is part of a larger effort by medical researchers to make the system more efficient and more affordable.

Earlier this month, researchers at Stanford University published a study that found that the Medicare program paid doctors only half as much for the same services as it did in the private sector.

This is especially important because Medicare pays doctors more than $10 billion a year to treat patients.

This new approach, which Jankwicks called the “Medicare Drug Free Approach,” could be used by doctors and other health care professionals to save $50 billion per year in the first year, and then the company hopes to pay a physician an additional $1 billion to make up for that.

“What we’re going for is the opposite of what Medicare pays,” Jinkiewicz said.

“That’s a lot of money, but it’s really, really inexpensive.”

A recent study from the University of Michigan’s Center for Health Innovation and Productivity found that Medicare pays about 10 percent of its costs on drugs.

And the government pays doctors about 15 percent of their costs.

The company has seen a surge in interest in drug discovery as the industry has struggled to find new drugs for the drug-resistant coronavirus, or COVID-19, and the aging population has started to increase.

In addition, patients have been more reluctant to see doctors than they were a decade ago.

“This is really a problem for the government,” Jinkingiewicz said, explaining that the federal government has only spent $6 billion on the research that led to the drugs.

“I think we have a really, very strong and credible case that we can do something with this.”

The company says it has spent more than 10 years working on the project, but that its team is now focused on scaling up to the point that it can actually make it happen.

“It’s not just about us building a product, it’s actually a huge engineering project,” Jankingowicz said.

The idea is to get patients into a system that pays doctors at least half as often as it pays pharmaceutical companies, and eventually give doctors a return on their investment in the program.

“If you’re a pharmacist, you’re going be paying 50 percent,” Janks said.

Jankowicz believes that the government has a lot more work to do to fix its Medicare program, and to bring patients into the system that will make their lives better.

The company says that by making the system efficient and accessible, it could save the government $10.5 trillion over the next 30 years.

“It would be amazing if you could make the whole system work better,” JANKOWSKI said.

The goal is to have the government pay doctors a higher rate of return on investment, which he says will be worth $100 billion to $200 billion a decade by 2036.

If that’s not enough to convince you, here’s how the company’s new model looks:Patients will be able to buy the company a service, and doctors will get a commission on the price they pay for that service.

And they’ll get paid for the difference between what doctors are paying and what the company pays for the service.

The difference will be a flat fee for a doctor and an increase in the amount the government spends to cover the cost.

The government will make money from these profits to provide drug discounts to doctors.

The government will also be able set a cap on the amount of money a doctor is allowed to charge a patient, based on the type of drug they prescribe.

This will give doctors incentive to make sure that patients get the right drug, which could reduce the number of prescriptions they have to fill.

“When I get a prescription, I don’t go to the pharmacy, I go to a doctor.

When a doctor makes a prescription for me, he has to take the medication, and I get it,” said Jankowski.

“So I think there’s some incentive for doctors to make better drug choices.”

The new system will be much cheaper to run than the existing system, Jankowksi said.

He says that with the new model, doctors would need to charge less than 20 percent of the cost of drugs for a patient.

“That would be a pretty big difference,” he said.

Jinkowski believes that he and his team can scale up to make this happen.